Predictors for Responsiveness to Corticosteroid in Patients With Early Acute Respiratory Distress Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-01-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In a recent multicenter randomized controlled trial, prolonged administration of low-dose methylprednisolone (1mg/kg/day) initiated in early acute respiratory distress syndrome was associated with earlier resolution of pulmonary and extrapulmonary organ dysfunction and reduction in duration of mechanical ventilation and intensive care unit stay. However, glucocorticoids may induce serious adverse events and these adverse events might compensate the positive effect of prolonged methylprednisolone infusion and discourage physicians from treating acute respiratory distress syndrome patients with glucocorticoids. Early prediction of responsiveness to prolonged methylprednisolone infusion would be help to decide whether to continue or not prolonged methylprednisolone infusion and this could reduce the drug related adverse events. We project to evaluate the predictors of responsiveness to prolonged methylprednisolone infusion in early acute respiratory distress syndrome .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Low Versus High Corticosteroid Use in Ventilator Associated Pneumonia

NCT04467892

Ventilator Associated Pneumonia

COMPLETED PHASE2

Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial

NCT04360876

COVID-19 ARDS

WITHDRAWN PHASE2

Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICU

NCT04163536

Chronic Obstructive Pulmonary Disease

RECRUITING PHASE3

Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia

NCT04344730

Acute Hypoxemic Respiratory Failure COVID-19

UNKNOWN NA

Long Term Outcome on Brain and Lung of Different Oxygen Strategies in ARDS Patients

NCT03621293

Acute Respiratory Distress Syndrome

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Respiratory Distress Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* AECC definition of acute respiratory distress syndrome
* Early acute respiratory distress syndrome (within 72 h of diagnosis)
* PF ratio \< 200 at PEEP ≥ 8 cmH2O

Exclusion Criteria

* Imminent death
* Contraindication to corticosteroid treatment
* Already on more than 0.5 mg/kg of methylprednisolone or its equivalent
* Evidence of uncontrolled infection
* Refusal of managing physician to participate in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No